Johnson & Johnson Stock Price, News & Analysis (NYSE:JNJ)

$142.60 1.46 (1.03 %)
(As of 12/13/2017 01:57 AM ET)
Previous Close$141.14
Today's Range$142.04 - $143.57
52-Week Range$110.76 - $144.35
Volume8.02 million shs
Average Volume5.87 million shs
Market Capitalization$384.67 billion
P/E Ratio19.69
Dividend Yield2.39%
Beta0.8

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:JNJ
CUSIP47816010
Phone+1-732-5242455

Debt

Debt-to-Equity Ratio0.36%
Current Ratio1.32%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E Ratio19.69
Forward P/E Ratio19.59
P/E Growth2.86

Sales & Book Value

Annual Sales$71.89 billion
Price / Sales5.33
Cash Flow$8.39 per share
Price / Cash16.99
Book Value$25.88 per share
Price / Book5.51

Profitability

Trailing EPS$5.76
Net Income$16.54 billion
Net Margins21.28%
Return on Equity27.38%
Return on Assets13.20%

Miscellaneous

Employees126,400
Outstanding Shares2,686,520,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Thursday, October 19th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share on Tuesday, December 12th. This represents a $3.36 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend is Monday, November 27th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings data on Tuesday, October, 17th. The company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts' expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business earned $1.68 earnings per share. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, October, 17th. The company provided EPS guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

18 brokerages have issued 12 month price targets for Johnson & Johnson's stock. Their predictions range from $110.00 to $165.00. On average, they expect Johnson & Johnson's stock price to reach $145.12 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "Sales in J&J’s domestic Pharma segment decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta are facing competition.  However, sales growth accelerated in Q3 and the positive trend is expected to continue in Q4. We believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry this year so far.  However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern." (12/12/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
  • 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer (Age 56)
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President (Age 59)
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President (Age 54)
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer (Age 55)
  • Michael H. Ullmann, Executive Vice President, General Counsel (Age 58)
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals (Age 54)
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer (Age 55)
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman (Age 58)
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director (Age 64)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.36%), Ameriprise Financial Inc. (0.65%), Legal & General Group Plc (0.54%), Schwab Charles Investment Management Inc. (0.45%), Fisher Asset Management LLC (0.44%) and Swiss National Bank (401,574.66%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Boston Partners, Prudential Financial Inc., American Century Companies Inc., Macquarie Group Ltd., Schroder Investment Management Group, State of Tennessee Treasury Department and Artisan Partners Limited Partnership. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including Stifel Financial Corp, APG Asset Management N.V., Assenagon Asset Management S.A., Sanders Capital LLC, Janus Henderson Group PLC, Capital International Investors, Schwab Charles Investment Management Inc. and Caisse DE Depot ET Placement DU Quebec. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $142.60.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $384.67 billion and generates $71.89 billion in revenue each year. The company earns $16.54 billion in net income (profit) each year or $5.76 on an earnings per share basis. Johnson & Johnson employs 126,400 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is 1 Johnson And Johnson Plz, NEW BRUNSWICK, NJ 08933-0001, United States. The company can be reached via phone at +1-732-5242455.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  500 (Vote Outperform)
Underperform Votes:  606 (Vote Underperform)
Total Votes:  1,106
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.302.272.32
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
13 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $142.55$138.91$130.05$124.26
Price Target Upside: 1.00% upside2.45% downside0.75% downside6.60% downside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/23/2017CitigroupBoost Price TargetBuy$140.00 -> $149.00N/AView Rating Details
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 -> $154.00N/AView Rating Details
10/16/2017Jefferies GroupBoost Price TargetBuy$157.00 -> $160.00N/AView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017Morgan StanleyReiterated RatingHold$140.00 -> $145.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 -> $155.00N/AView Rating Details
10/18/2017Stifel NicolausBoost Price TargetHold -> Hold$140.00 -> $142.00N/AView Rating Details
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$144.00 -> $147.00N/AView Rating Details
10/18/2017Leerink SwannReiterated RatingOutperform -> Outperform$150.00 -> $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/20/2017Goldman Sachs GroupDowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
8/16/2017J P Morgan Chase & CoBoost Price TargetOverweight$140.00 -> $148.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
8/19/2016Deutsche BankReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James FinancialReiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
1/27/2016Independent ResearchSet Price TargetNeutral$108.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018$1.72N/AView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.29 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2017 EPS Consensus Estimate: $7.08
2018 EPS Consensus Estimate: $7.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20172$1.75$1.86$1.81
Q3 20171$1.84$1.84$1.84
Q4 20171$1.69$1.69$1.69
Q1 20181$1.99$1.99$1.99
Q2 20181$2.01$2.01$2.01
Q3 20181$2.18$2.18$2.18
Q4 20181$1.81$1.81$1.81
(Data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Most Recent Dividend:12/12/2017
Annual Dividend:$3.36
Dividend Yield:2.36%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:58.33% (Trailing 12 Months of Earnings)
46.15% (Based on This Year's Estimates)
42.80% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.89%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
Markets Right Now: Banks lead US stock indexes mostly higherMarkets Right Now: Banks lead US stock indexes mostly higher
marketbeat.com - December 12 at 4:30 PM
Stocks Mixed As Nasdaq Struggles, But These 2 Sectors OutperformStocks Mixed As Nasdaq Struggles, But These 2 Sectors Outperform
finance.yahoo.com - December 12 at 3:17 PM
Johnson & Johnson (JNJ) PT Raised to $161.00Johnson & Johnson (JNJ) PT Raised to $161.00
www.americanbankingnews.com - December 12 at 3:16 PM
Johnson & Johnson (JNJ) Downgraded by Zacks Investment ResearchJohnson & Johnson (JNJ) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 12 at 12:06 PM
Lilly Reports Mixed Results from Late-Stage Cyramza StudyLilly Reports Mixed Results from Late-Stage Cyramza Study
finance.yahoo.com - December 11 at 3:17 PM
Here's Why Syros Pharmaceuticals Got Crushed TodayHere's Why Syros Pharmaceuticals Got Crushed Today
finance.yahoo.com - December 11 at 3:17 PM
ImmunoBiochem Corporation Announces the Completion of a New Round of Financing and Residency at Johnson & Johnson Innovation, JLABS @ TorontoImmunoBiochem Corporation Announces the Completion of a New Round of Financing and Residency at Johnson & Johnson Innovation, JLABS @ Toronto
www.prnewswire.com - December 11 at 12:22 PM
Johnson & Johnson files U.S. marketing application for expanded label of blood thinner XareltoJohnson & Johnson files U.S. marketing application for expanded label of blood thinner Xarelto
seekingalpha.com - December 11 at 10:59 AM
Will Johnson & Johnson Raise Its Dividend in 2018? The Motley Fool - Motley FoolWill Johnson & Johnson Raise Its Dividend in 2018? The Motley Fool - Motley Fool
www.fool.com - December 10 at 5:58 AM
Will Johnson & Johnson Raise Its Dividend in 2018?Will Johnson & Johnson Raise Its Dividend in 2018?
www.fool.com - December 9 at 11:32 AM
Johnson & Johnsons (JNJ) Healthy Quant Score Keep it a Buy - Investorplace.comJohnson & Johnson's (JNJ) Healthy Quant Score Keep it a Buy - Investorplace.com
investorplace.com - December 9 at 5:59 AM
Reviewing Juniper Pharmaceuticals (JNP) & Johnson & Johnson (JNJ)Reviewing Juniper Pharmaceuticals (JNP) & Johnson & Johnson (JNJ)
www.americanbankingnews.com - December 9 at 1:48 AM
What To Make Of J&Js First Xarelto Lawsuit LossWhat To Make Of J&J's First Xarelto Lawsuit Loss
finance.yahoo.com - December 8 at 3:17 PM
Johnson & Johnson: Reliable Dividend Clipper - Seeking Alpha - Seeking AlphaJohnson & Johnson: Reliable Dividend Clipper - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 8 at 6:19 AM
Johnson & Johnson (JNJ) Management Presents at Citi Global Healthcare Conference - Seeking AlphaJohnson & Johnson (JNJ) Management Presents at Citi Global Healthcare Conference - Seeking Alpha
seekingalpha.com - December 8 at 6:19 AM
J&J Faces High-Stakes Appeal to Toss Pinnacle Hips JudgmentJ&J Faces High-Stakes Appeal to Toss Pinnacle Hips Judgment
finance.yahoo.com - December 7 at 3:18 PM
Roche Reports Tecentriq/Avastin Lung Cancer Study DataRoche Reports Tecentriq/Avastin Lung Cancer Study Data
finance.yahoo.com - December 7 at 3:18 PM
Dow Movers: HD, JNJDow Movers: HD, JNJ
www.nasdaq.com - December 6 at 3:17 PM
The Healthcare Sector: Will the Rally Continue in December?The Healthcare Sector: Will the Rally Continue in December?
finance.yahoo.com - December 6 at 3:17 PM
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
finance.yahoo.com - December 6 at 3:17 PM
Drug Companies From Glaxo to J&J Pledge to Make U.K. InvestmentsDrug Companies From Glaxo to J&J Pledge to Make U.K. Investments
finance.yahoo.com - December 6 at 6:27 AM
Biotech Stocks May See a New M&A Wave in 2018Biotech Stocks May See a New M&A Wave in 2018
finance.yahoo.com - December 5 at 3:18 PM
The Outlook For Johnson & Johnsons Immunology Drug BusinessThe Outlook For Johnson & Johnson's Immunology Drug Business
finance.yahoo.com - December 5 at 3:18 PM
Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuitJury orders Bayer, J&J to pay $28 million in Xarelto lawsuit
finance.yahoo.com - December 5 at 3:18 PM
Jury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsuitJury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsuit
finance.yahoo.com - December 5 at 3:18 PM
Will 2018 Be Johnson & Johnsons Best Year Yet? -- The Motley Fool - Motley FoolWill 2018 Be Johnson & Johnson's Best Year Yet? -- The Motley Fool - Motley Fool
www.fool.com - December 5 at 5:59 AM
3 Dividend Stocks That Pay You More Than Johnson & Johnson Does3 Dividend Stocks That Pay You More Than Johnson & Johnson Does
www.fool.com - December 4 at 6:46 PM
Interesting June 2018 Stock Options for JNJInteresting June 2018 Stock Options for JNJ
www.nasdaq.com - December 4 at 3:17 PM
Will 2018 Be Johnson & Johnson's Best Year Yet?Will 2018 Be Johnson & Johnson's Best Year Yet?
finance.yahoo.com - December 4 at 3:17 PM
Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke PreventionAmgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention
finance.yahoo.com - December 4 at 3:17 PM
Will 2018 Be Johnson & Johnsons Best Year Yet?Will 2018 Be Johnson & Johnson's Best Year Yet?
www.fool.com - December 4 at 6:20 AM
Idorsia to get $230 million from J&J in latest hypertension deal - ReutersIdorsia to get $230 million from J&J in latest hypertension deal - Reuters
www.reuters.com - December 4 at 6:09 AM
50,000 New Drug Tests Among Brexit Worries for Pharma Companies50,000 New Drug Tests Among Brexit Worries for Pharma Companies
finance.yahoo.com - December 4 at 6:09 AM
Idorsia to get $230 mln from J&J in latest hypertension dealIdorsia to get $230 mln from J&J in latest hypertension deal
finance.yahoo.com - December 4 at 6:09 AM
Idorsia to get $230 million from J&J in latest hypertension dealIdorsia to get $230 million from J&J in latest hypertension deal
finance.yahoo.com - December 4 at 6:09 AM
Better Buy: Pfizer Inc. vs. Johnson & Johnson -- The Motley Fool - Motley FoolBetter Buy: Pfizer Inc. vs. Johnson & Johnson -- The Motley Fool - Motley Fool
www.fool.com - December 2 at 7:36 AM
[$$] Savvy Teacher, Smart Student[$$] Savvy Teacher, Smart Student
finance.yahoo.com - December 2 at 7:36 AM
3 Drug/Biotech Stocks in Focus on World AIDS Day3 Drug/Biotech Stocks in Focus on World AIDS Day
finance.yahoo.com - December 2 at 7:36 AM
[$$] After a Banner Year, J&J Can Still Rise Further[$$] After a Banner Year, J&J Can Still Rise Further
finance.yahoo.com - December 2 at 7:36 AM
Missouri Judge Upholds $110M Talcum Powder Jury Award Against Johnson & Johnson (JNJ)Missouri Judge Upholds $110M Talcum Powder Jury Award Against Johnson & Johnson (JNJ)
www.streetinsider.com - December 1 at 3:18 PM
Johnson & Johnson (JNJ) a Buy on Solid Quant ScoreJohnson & Johnson (JNJ) a Buy on Solid Quant Score
investorplace.com - December 1 at 3:18 PM
Glaxo Begins Phase III Study on Injection to Prevent HIVGlaxo Begins Phase III Study on Injection to Prevent HIV
finance.yahoo.com - December 1 at 3:18 PM
Better Buy: Pfizer Inc. vs. Johnson & JohnsonBetter Buy: Pfizer Inc. vs. Johnson & Johnson
finance.yahoo.com - December 1 at 3:18 PM
Johnson & Johnson (JNJ) Receives Average Rating of "Hold" from AnalystsJohnson & Johnson (JNJ) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 1 at 11:34 AM
Genmab and Johnson & Johnson love partnership as some ponder ... - ReutersGenmab and Johnson & Johnson 'love' partnership as some ponder ... - Reuters
www.reuters.com - December 1 at 6:24 AM
Missouri Judge Upholds $110M Talcum Powder Jury Award Against ... - StreetInsider.comMissouri Judge Upholds $110M Talcum Powder Jury Award Against ... - StreetInsider.com
www.streetinsider.com - December 1 at 6:24 AM
Top Defensive Consumer Stocks for 2017Top Defensive Consumer Stocks for 2017
finance.yahoo.com - December 1 at 6:24 AM
Judge rules Talcum powder case has jurisdiction in St. LouisJudge rules Talcum powder case has jurisdiction in St. Louis
marketbeat.com - November 30 at 6:36 PM
Johnson & Johnson to Participate in the BMO Capital Markets Healthcare ConferenceJohnson & Johnson to Participate in the BMO Capital Markets Healthcare Conference
www.prnewswire.com - November 30 at 3:58 PM
Missouri Judge Upholds $110 Million Talc VerdictMissouri Judge Upholds $110 Million Talc Verdict
finance.yahoo.com - November 30 at 3:17 PM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.